4//SEC Filing
Powell Andrew Kenneth William 4
Accession 0001209191-24-004385
CIK 0001557746other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:58 PM ET
Size
7.2 KB
Accession
0001209191-24-004385
Insider Transaction Report
Form 4
Powell Andrew Kenneth William
Director
Transactions
- Purchase
Common Stock
2024-03-01$1.23/sh+8,500$10,455→ 22,863 total - Purchase
Common Stock
2024-03-04$1.25/sh+6,000$7,500→ 28,863 total
Footnotes (2)
- [F1]The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.2393, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.269, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Documents
Issuer
Aclaris Therapeutics, Inc.
CIK 0001557746
Entity typeother
Related Parties
1- filerCIK 0001304113
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 4:58 PM ET
- Size
- 7.2 KB